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ABSTRACT 
 BACKGROUND 
In our country,there is a huge burden due to asthma  and a huge proportion of 
these  cases  are left underrecognised,underestimated and undertreated.Asthma is 
now considered a single airway disease and hence comprehensive 
diagnosis,treatment  and follow up is essential.Majority of asthma patienys are atopic 
according to population studies.The prevalence of asthma increases with increasing 
severity of asthma according to population studies.In asthma patients eosinophils are 
present in blood,sputum,bronchiallavage.Further studies are required to prove its 
association with severity of asthma 
 
AIMS AND  OBJECTIVES 
1. To establish an association between airway inflammation as   assessed by absolute 
eosinophil count and disease severity. 
2. To establish an association between atopy as      demonstrated by serum 
Immunoglobulin E levels and  disease severity. 
3. To correlate the clinical presentation, Serum IgE and   absolute eosinophil count 
with severity of bronchial asthma as assessed by lung spirometry. 
4. To predict the prognosis and treatment outcome of bronchial asthma patients from 
absolute eosinophil count and serum Ig E levels. 
 
 
 
Methodology 
 100 patients who were diagnosed to have bronchial asthma in 
Coimbatore Medical College hospital were included in the study 
population. Risk factors, family history and other associated comorbid 
conditions were recorded .Severity was assessed by doing lung spirometry 
in all patients.Serum immunoglobulin E and absolute eosinophil count was 
done in patients for those classified into mild, moderate and severe 
groups.Correlation was assessed between each of these variables and 
severity. 
Results 
 Positive correlation was found between asthma severity and absolute 
eosinophil count in the severe persistent asthma group which was statistically 
significant.SerumIgE levels correlate with asthma severity and the mean Ig E in mild 
was 271.50 IU/mL,moderate group was 916.48 IU/mL and severe group was 1662.59 
IU/mL. 
 
 
 
 
Conclusion 
     Serum immunoglobulin E and absolute eosinophil counts were found to 
have positive correlation with asthma severity. Estimation of these 
parameters can be used as simple tools in assessing asthma severity based 
on clinical grading. 
 Key words-Bronchial asthma,Absolute Eosinophil Count,Serum 
immunoglobulin E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
INTRODUCTION 
Over the last few years, an increase in prevalence of  allergic 
diseases  like asthma and allergic rhinitis is seen. Both are common 
chronic diseases that affect the quality of  life of  patients and have a 
significant economic impact. About 300 million people worldwide suffer 
from asthma and this figure is projected to rise to 400 million by year 
2025. 
Nearly 5 Lakh people are hospitalised  a  year and nearly  250000  
deaths occur due to the disease. Around 35% is  the  prevalence  of 
allergic rhinitis in Europe and Australia . It shows a significant impact on 
people day to day life  and if untreated it can lead to many symptoms. 
     In our country, there is a huge burden due to asthma  though 
further data is required for finding out prevalence. Asthma Epidemiology 
Study Group of Indian Council of Medical Research found the prevalence 
of bronchial asthma in Indian adults as 2.38 %.  
Today, our country’s census is  above  1   billion . This exploding 
of census itself suggests  a  huge  increase  of allergic diseases in our 
country which  are left under recognised, underestimated and under 
treated in India. 
Presently, bronchodilators  and  anti-inflammatory drugs  are 
providing relief in majority of patients, though  they  do not produce 
  
 
symptomatic relief to all patients. Despite the various treatment options 
available those in mild to severe group continue to have excacerbations 
with inhaled therapies, leading to large number of hospitalisations and 
visit to  physicians 
As there exists many asthma mimics, diagnosis of asthma needs 
supporting evidences like family history, history of allergy etc. Asthma 
now considered as single airway disease and hence comprehensive 
diagnosis, treatment and follow up of upper and lower respiratory tract is 
essential. 
It has been observed in many studies that  serum Ig E level is 
elevated in asthmatic and tracks with the severity of asthma. Eosinophil 
infiltration is hallmark feature of pathogenesis of asthma which are the 
triggers for the chronic airway inflammation and are raised in acute 
exacerbations and hence assessing  eosinophil count is evidence of 
serological markers for Airway inflammation . Hence this study was 
undertaken in areas of Coimbatore where such studies are not done 
previously. 
 In asthma patient, eosinophils are present in  blood, sputum, 
bronchial lavage and bronchial biopsy specimens, and increase in 
number correlate with disease severity, airway obstruction and 
bronchial hyper reactivity. 
  
 
 
 Atopy, the propensity to produce a higher  amount of Ig E in 
response to allergens appear to be greatest risk 
 
 Population studies have shown that majority of children and adults 
with asthma are atopic, though  it may occur in few non atopic 
individuals with no positive skin tests or raised serum Ig E levels. 
 
 Population studies have also shown that prevalence of asthma 
increase with increasing levels of Ig E and those with low levels of 
serum Ig E have low prevalence of asthma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
AIMS AND OBJECTIVES 
 
1. To establish an association between airway inflammation as 
assessed by absolute eosinophil count and disease severity. 
2. To establish an association between atopy as  demonstrated by 
serum Immunoglobulin E levels and  disease severity. 
3. To correlate the clinical presentation, Serum IgE and  absolute 
eosinophil count with severity of bronchial asthma as assessed by 
lung spirometry. 
4. To predict the prognosis and treatment outcome of bronchial 
asthma patients from absolute eosinophil count and serum Ig E 
levels. 
 
 
 
 
 
 
 
 
 
 
  
 
REVIEW OF LITERATURE 
 
     Bronchial asthma is an airway  disease  with  episodic, reversible 
bronchial obstruction, interspersed with symptom free period. It is caused  
by  increased  responsiveness  of  tracheobronchial  tree to various stimuli 
leading  to spasmodic  narrowing  of  airways . It is manifested clinically 
as  paroxysms  of  wheeze, cough and dyspnea
01
.  
 
 
 
Fig 1 :  Normal Anatomy of airways 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2 : Conducting and non conducting airways 
 
 
 
 
 
  
 
 
 
Fig  3 : Airway in normal individuals and asthma 
 
PREVALENCE 
         Bronchial asthma is present world wide.It affects around 300 
million people now across the globe. Its prevalence has increased in 
developed countries over 30 years and  will increase by additional 100 
million by 2015
02
. Nearly 10%adults  and  15% children are affected by 
the disease. African americans are more likely than Caucasians to be 
admitted and have a higher mortality rate. Majority of patients in 
devoloped countries are atopic with allergic sensitizations to 
environmental allergens. Asthma is  mostly complicated by smoking 
effects on lungs ,so it is difficult to be sure about the natural history of 
  
 
disease in adults. Asthma can present at any age, with a peak at 3 years. 
In childhood, males  are twice affected than  females , but  in adults the 
sex ratio equalizes. It is commonly  believed  that children "grow out of 
their asthma " . Long-term trials  that have followed children until they 
reach  40 years suggest that many with asthma become asymptomatic 
during adolescence but that asthma returns in some during adult life. 
Adults with Asthma including those with onset during adulthood, rarely 
become permanently asymptomatic. The severity of asthma does not vary 
significantly within a given patient; those with mild asthma rarely 
progress to more severe disease. 
The International Study of Asthma and Allergies in Childhood 
(ISAAC)worked up  prevalence of symptoms, specifically wheezing, in  
13 to14 year aged in 155 centers  throughout the world and prevalence 
rate was  found  ranging from <5% to nearly 40%. In United States ,at 
least one of every 20 individuals suffer from asthma. Over the last two 
decades its prevalence has increased 61%
03
. It is a leading cause of  
chronic illness in children. It causes nearly a loss of 10 million school 
days and 3 million work days.  Since 1980, deaths from asthma has 
increased by  31%. 
 
 
  
 
  
 
 
Fig  4 : Prevalence and mortality worldwide 
  
 
 
 
 
Figure  5 :Asthma emergency department  visits (top) and 
hospitalizations (bottom) per 10,000 populations, 2014. 
Hospitalizations are  three time  more frequent and emergency 
department visits almost five times more frequent among blacks.  
Hospitalizations are more frequent in children than adults. 
Source:  National Hospital Ambulatory Medical Care Survey, 
National Center for Health Statistics, Centers for Disease Control , 
age adjusted to 2012 population. 
 
  
 
 
HISTORY OF ASTHMA 
                The meaning of greek word asthma  is “breath hard” /“to 
pant”
04
. Hippocrates was the first to recognize  spasmodic nature of 
the disease and thought its onset was due to climate change and 
occupation.Malinonides, physician of the Sultan of Egypt in the 12th 
century believed that successful treatment of asthma required a 
thorough knowledge of patient, his hygiene, diet, medication, personal 
behavior etc. He also felt that mental factors could have an adverse 
effect on a patient’s physical health, including respiratory functions
02
. 
In the past asthma was synonymously used for dyspnea as well. 
                    It was Henry Hyde Salt (1860) in his book “On Asthma, 
its Pathology and Treatment” gave a vivid comprehensive description 
and separated asthma from dyspnoea. He separated the idiopathic 
uncomplicated spasmodic asthma from symptomatic or complicated 
asthma (organic asthma). He recognized that the former arouse most 
commonly in childhood. He blamed inhalation of dust, hay, fur, 
feather and a large psychological overlay as well.In 1968 Sir Joh 
Flover in his book “A Treaties of Asthma’ have said asthma is due to 
the constriction of bronchi. He also distinguished between different  
types of asthma by contrasting continuous asthma with periodic or 
convulsive asthma. He also found that elements of the environment 
  
 
could trigger asthma attacks.In 1862 the American thoracic society, 
New York  defined bronchial asthma  as disease characterized by an 
increased responsiveness of trachea and bronchi to various stimuli 
manifested by wide spread narrowing of airways that changes in 
severity either spontaneously or as a result of therapy” .In 1967 -short 
acting  β 2 receptor agonist was discovered and was used in the 
treatment of asthma.In 1968, WHO officially declared  IgE as 5th 
immunoglobulin isotype. and Sodium chlomoglycolate was introduced 
as a mast cell stabilizer thus offering a new approach to asthma 
management.In 1972- Inhaled steroids were introduced into the 
treatment of asthma as potent anti-inflammatory agent.In 1982- 83- 
Independent groups successfully identified the structure of the slow 
substance of anaphylaxis (SRS-A) believed to be the missing mediator 
of asthma. Nobel Prize was awarded for this discovery. 
 
 
 
 
 
 
 
 
 
  
 
 
ETIOLOGY 
                 Asthma has both endogenous and environmental factors 
involved in its complex etiology. Among the endogenous factors atopy 
has been implicated as a major risk factor
02
. But even non atopic persons 
develop asthma though the risk is less. Most  common  allergens are 
house dust, animal fur, pollen grains. Atopy is due to increased Ig E 
production in response to allergens. 
        Apart  from  genetic factors, allergens, respiratory  infections, indoor 
and outdoor  air pollutants, even low maternal age and  low birth weight 
,duration of  breast feeding and physical inactivity are associated in its 
etiology. 
Genetics of asthma: 
More than 100 genes are found to be  be associated.  
   
•
 
 
 
 
• Chromosome 5q is the  most replicated susceptibility loci
05
 
 
• Class II HLA alleles has been found to produce IgE response to 
ragweed pollen 
 
• ADAM-33
06
, a metalloproteinase produced by bronchial smooth 
muscles has been associated with airway hyperresponsiveness and 
bronchoconstriction. 
 
• Mammalian chitinase -This enzyme  triggers inflammatory mediators 
 
 
 
  
 
 
 
 
 
 
 
Fig 6 : Protective and predisposing factors 
 
 
 
  
 
 
Fig  : 7 Etiology of asthma 
 
 
 
 
 
 
  
 
RISK FACTORS FOR ACUTE SEVERE ASTHMA
07
 
 
Keller et al had shown in his studies that in asthma of severe 
asthma, lack of private insurance and female sex all increase admission 
risk to hospital. 
But studies by Robertson et al showed that,asthma of any severity in 
adults or children can lead to a fatal attack,both in children and adults. 
Nearly upto 13%adults and 23% children with mild asthma can have a 
life threatening attack of asthma. Various other precipitants requiring 
mechanical ventilation are  
• Upper respiratory infection(61%) 
• Exposure to Allergen/smoke 
• Compliance related problems 
• Drug  abuse 
 
In study of Keller Et al ,it was also noticed that age, race, month of 
admission ,smoking exposure in family and family history of atopy places 
a child at no higher risk for an intensive care admission. Chronic use of 
β2 agonists in asthmatic patients has been found to cause increased 
asthma related deaths. 
 
 
  
 
PATHOGENESIS 
08
 
• In  asthma ,there  is chronic inflammation  of  lower airway 
mucosa.  
• Airway hyperresponsiveness ,which is the major physiological 
abnormality in asthma ,causes  activation of  mucosal  mast cells 
and  infiltration of mucosa  with  T lymphocyes and activated 
eosinophils. 
• From trachea to terminal bronchioles inflammation occurs ,but  
cartilaginous airways like  bronchi are mostly involved.  
• Pathophysiology of asthma is complex mediated by interaction of 
several inflammatory cells leading to acute and chronic 
inflammation of airways. 
  
 
 
Figure  8 : Cellular and structural components 
 
 
 
 
 
 
  
 
 
 
 
Fig  9 :  Histopathology Of Small Airway In Asthma 
  
 
 
 
 
 
Figure  10 :  Pathogenesis of asthma 
  
 
 When allergen is inhaled by an  atopic  patient , a  two-phase 
bronchoconstrictor response is seen . Rapid interaction of allergen with 
mucosal mast cells occurs byan  IgE mediated mechanism. Inflammatory 
mediators like histamine,prostaglandins,cytokines,chemokines cause  
increase microvascular leakage ,plasma exudation, increased mucus 
production forming viscid mucous plugs inturn causing airway 
obstruction, bronchospasm and attract various other inflammatory 
mediators.Airway remodelling occurs leading to changes in structure of 
airways  finally causing irreversible airway narrowing and consequent 
decrease in lung function
09
. Increased airway smooth muscle,fibrosis, 
mucus hyperplasia are seen. 
 
 
 
 
 
 
 
 
  
 
 
Figure 11 : Inflammatory cells, mediators and effects 
 
Figure 12 : Hypersensitivity reaction in asthma 
 
  
 
TYPES  
 
Atopic Asthma (Extrinsic asthma) 
• Most common type of asthma also called early onset asthma
07
.  
 
• Dusts, pollens, cock roach or animal fur, and food are triggers.  
 
• Members of family will have history 
 
Non-Atopic Asthma 
• Skin tests are usually negative
07
 though there is evidence of 
allergy sensitisation.  
 
• In family members disease is unlikely. 
 
•  Respiratory infections caused by  viruses can predispose. 
 
• Pollutants of air also lead to this type of asthma. 
 
 
Drug-Induced Asthma 
     Many drugs can  provoke asthma.  
• Aspirin sensitive asthma
09
, is seen in people who have polyps in 
nose and nasal obstruction, sneezing, rhinitis periodically. 
• Mechanism is that aspirin  inhibits  the cyclooxygenase pathway 
of arachidonic acid metabolism without affecting the lipoxygenase 
route, thus  activating the bronchoconstrictor leukotrienes. 
• Aspirin-sensitive asthma responds to usual therapy with ICS.  
• Antileukotrienes  are useful in these patients, they are no more 
effective than in allergic asthma. 
• Rarely, aspirin desensitization is needed, but it should  be 
undertaken only inspecialized center. 
  
 
 
 
Figure 13 : Drug induced asthma 
Occupational Asthma 
• Fumes of petrochemicals and various chemicals can trigger asthma.  
• Very less quantities of exposure  can  induce  attack, but usually  it 
occurs after repeated  exposure. 
  
• Type I hypersensitivity reaction  lead to release of 
bronchoconstrictor  substances
07
.  
Figure 14 : Occupation and asthma triggers 
 
 
 
 
 
 
 
  
 
CLINICAL FEATURES 
Symptoms  are 
• Widespread polyphonic wheeze - Expiratory wheeze is heard with 
mild bronchoconstriction, both inspiratory and expiratory in 
moderate and inspiratory in severe type. 
 
• In near fatal asthma chest is silent. 
 
 
• All wheezes are not due to asthma. Other disorders producing 
wheeze  are chronic obstructive pulmonary disease, cardiac 
asthma, allergic bronchopulmonary aspergillosis, eosinophilic 
pneumonias, carcinoid tumors and recurrent pulmonary emboli. 
 
Nocturnal asthma   
• Total decrease of greater than 20% in FEV1 or PEFR.It may be the 
only manifestation of asthma. 
• Mechanism 
 
 Due to early morning decrease in circulating adrenaline, 
 Increased vagal tone in early morning 
 Airway cooling at night time 
 Circadian changes in plasma cortisol levels(midnight to early 
morning fall in cortisol levels). 
 
 
  
 
• Worsening of asthma after meals or dyspnea  occurring only after 
meals due to gastroesophagal reflex is gastric asthma. Symptoms 
may be chronic unless controlled by appropriate therapy. 
 
• Catamenial asthma occur in females  at  times of  menstrual 
cycle.  
 
 
Exercise-induced Asthma 
 
• Heavy exertion, mainly in cold climate, is highly suggestive of 
exercise-induced asthma. 
•  Typically, patient experiences symptom at the end of exercise, 
rather than  during exercise
08
. 
• Persistent cough  following  exercise, in absence of wheezing, 
may also  be a sign of asthma. 
 
 
 
Figure 15 :  Exercise-induced asthma. 
 
 
 
  
 
Aspirin induced asthma-   
 
• In contrast to classic atopic asthma, which patients usually develop 
before the age of 20, aspirin induced asthma  typically occurs in 
individuals in the fourth decade of life.  
 
• Thus, it  appears to be  an acquired disease
09
. 
 
•  In general, these patients do not have a prior history of exposure 
and potential sensitization to NSAIDs.  
 
• Familial predisposition is also rare; in one study, a positive family 
history was noted in only 2 of 500 patients. 
 
Associated conditions with asthma: 
 
• Rhinosinusitis with or without nasal polyps is mostly present and 
should be treated with saline rinsing, antihistamines and 
corticosteroids given intranasally
10
. 
• Vocal cord dysfunction can coexist with severe attacks of asthma. 
Speech therapy and behavioural therapy is beneficial. 
• Obesity is well recognised as a comorbid condition and can worsen 
asthma control. It can be related to altered lung mechanisms, 
respiratory pattern, or increase in systemic inflammation. Obesity 
should be controlled by weight loss and exercise in such patients. 
• There is no much variation in asthma prevalence as general 
population. Though there is no studies proving direct link between 
  
 
tobacco use and development of  asthma ,its use can make patients 
less responsive to corticosteroids and make it difficult to control. 
Therefore tobacco cessation should be encouraged in all patients. 
• Symptomatic gastroesophagal reflex disease can cause cough and 
wheeze in few patients. Treatment with H2 blockers or proton 
pump inhibitors are useful. Empirical treatment of  gastroesophagal 
reflex disease in such patients is not of use. 
• Asthma may be difficult to control if associated with obstructive 
sleep apnea  and should be assessed with overnight 
polysomnogram if there is suspicion.  
• Approach to allergic rhinitis and asthma 
• Atopy has  a role in their co existence but it is not a prerequisite. 
 
1. When to suspect AR coexisting with BA?
11
 
 Recurrent sore throats 
 Hoarseness of  voice 
 Snoring 
 Persistent mouth breathing 
 Pain/pressure over sinuses 
 Persistent headaches 
 Recurrent otitis media especially in children 
 Cough especially in children 
 Halitosis. 
 Poor sleep and daytime fatigue 
  
 
 Persistent respiratory symptoms inspite of controlled asthma and 
normal lung spirometry 
 
2. When  to investigate AR with BA? 
 In poor asthma control in spite of appropriate treatment and good 
adherence 
 Skin allergies or eczema which are difficult to treat 
 Persistent nasal obstruction, congestion, postnasal drip, reduced 
smell  sensation  for >12 weeks
11
 
 Persistent rhinitis which does not  respond to a trial of intranasal 
corticosteroids 
 Persistent epistaxis unilaterally-tumors,vasculitis or granuloma 
 Diffuse nasal polyps with or without asthma history 
 
3. If any of above conditions are present, following tests are 
suggested
12 
 
1. Repeat spirometry pre and post bronchodilator. 
2. Routine haematological and radiological tests 
3. Allergy tests-Skin prick tests or allergen specific Ig E/RAST 
4. CT Scan to rule out intranasal pathology 
Acute severe asthma (Status asthmaticus) 
• It is a medical emergency. 
 
• Patient is too dyspneic to speak, hypoxic and cyanosed due to 
severe bronchospasm.  
 
• It is characterised by tachycardia, tachypnea
12
, sweating, pulsus 
paradoxus, and altered level of consciousness. 
 
  
 
• Fall in spirometry values are seen. Normal or rising PCO2 warns 
of an  impending respiratory failure.It requires prompt monitoring 
and treatment. 
 
• Chest Xray is not of much help, occasionally pneumothorax or 
pneumonia may be present. 
 
• Spirometric values will fall, PEF will be  < 40% predicted.   
 
Severity level assessment of acute asthma excacerbation 
Near fatal asthma-High or rising  PC02 ,On ventillatory support 
 
       Life threatening asthma  - 
 
• Peak expiratory flow of <33% based unpredicted as P02< 
92%, Pa02 < 60mm Hg
12
 
• Normal PaC02 35-45 mm Hg 
 
• Silent chest 
 
• Cyanosis 
 
• Feeble respiratory effort 
 
• Bradycardia 
 
• Dysrhythmia 
 
• Hypotension 
 
• Exhaustion 
 
• Drowsiness 
 
• Confusion 
 
• Coma 
 
  
 
REFRACTORY ASTHMA 
• This category includes patients, not  attaining relief even with high 
dose of inhalations 
CAUSES OF REFRACTORY ASTHMA 
1.Upper airway obstruction
11
 
      a)Tumors 
      b)Epiglottitis 
      c)  Vocal cord dysfunction 
      d) Obstructive sleep apnea 
2.Tracheomalacia 
3.Endobronchial leision 
4.Foreign body 
5.Congestive cardiac failure 
6.Gastroesophagal reflex 
7.Sinusitis 
8.Herpetic tracheobronchitis 
9.Adverse drug reaction 
• Aspirin 
• Angiotensin converting enzyme inhibitors 
• Inhaled pentamidine 
10.Allergic bronchopulmonary aspergillosis 
11.Hyperventillation with panic attacks 
  
 
DIFFERENTIAL DIAGNOSIS BASED ON HISTORY AND 
CLINICAL  FINDINGS 
HISTORY     POSSIBLE DIAGNOSIS 
• Symptomatic since birth          1. Cystic fibrosis
12
 
                                   2. Primary Ciliary dyskinesia. 
         3. Gastroesophagal reflex. 
   
•   Positive family history                   1. Cystic fibrosis. 
  of uncommon  airway  disease         2. Airway or lung malformation 
 
• Acute onset with no prexisting    1. Aspiration of foreign body 
problems 
 
SYMPTOMS 
• Upper airway symptoms,fever                 Acute airway infection 
• Bronchitis 
• Bronchiolitis 
• Pneumonia 
• Dysphagia,heart burn,vomiting,          Aspiration,GERD  
cough 
 
• Abnormal hoarseness of voice      Laryngeal or vocal cord disease 
 
• Inspiratory and expiratory stridor    1.Laryngitis 
                                                                       2.Tracheitis 
       3.Laryngomalacia/tracheomalacia 
  
 
• Failure to thrive                       Cystic fibrosis,immune deficiency  
                     Lung malformation 
 
• Sleep predominant        Upper airway disease(post nasal    
symptoms                                   drip, GERD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Complications of asthma 
 
• Patient goes to dehydrated state. 
 
• Infection of airways 
13
 
 
• Tussive  syncope 
•  Rarely  pneumothorax 
 
• Respiratory failure . 
 
INVESTIGATIONS 
Chest Xray 
 Usually normal except in severe cases, when there is hyperinflated 
lung fields. 
Blood tests 
1. Peripheral blood eosinophil count: 
 
• Absolute eosinophil count (greater than 4 percent or 300 to 400 
permm3) may be seen in both allergic and nonallergicasthmatics
15
.  
 
• When present, eosinophilia may be usedto support a diagnosis of 
asthma; however, its absence is of no value in excluding asthma
16
.  
 
• Unusually high eosinophil counts (greater than 800 permm  
3) suggest the presence of otherdisorders, such as allergic 
bronchopulmonary aspergillosis, Churg-Strauss syndrome, tropical 
eosinophilia, and Loeffler’s syndrome. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure  16 : Eosinophils  under light microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
SERUM IgE 
 
 
• Epidemiologic studies have demonstrated an association between 
asthma and total serum immunoglobulin E (IgE) levels, 
standardized for age and sex. 
 
• Whether this association signifies that  aeroallergens are prominent 
etiological factors, or that immunologic processes in the 
pathogenesis of asthma  are capable of stimulating IgE 
production
19
  as an unrelated phenomenon  needs further definition.   
 
 
                   Figure  17 : Structure of  IgE 
 
 
 
 
  
 
                   
• Studies have also shown a relationship between total serum IgE 
and asthma  in  patients  with negative skin tests.   
• In addition, other studies have reported that elevations in total IgE 
are strongly associated with asthma, whereas skin test reactivity is 
more closely related to allergic rhinitis 
20
. 
• Importantly, IgE levels are used to calculate the dose of the anti-
IgE antibody omalizumab,when it is used for asthma treatment 
• It should be noted that eosinophilia
21
 may not be present if the 
patient is taking corticosteroid 
 
 
Sputum Examination 
 
In research studies ,sputum eosinophil counts have been shown to 
predict clinical outcomes, particularly exacerbations when corticosteroids 
are withdrawn, but more research needs to be done before sputum 
examination can be used as diagnostic tool. 
 
Allergy Tests 
 
Tests to determine whether the patient is allergic and to investigate 
the role of specific allergens as a cause of asthma are of value in some 
patients. 
 
  
 
       In selected populations, evaluations for perennial or indoor allergens, 
such as dust mite, cockroach, or animal dander have become increasingly 
important.  
 
 
A study done by Das B.K., Kumar S.. Panda B.K.. Misira O.P  in 
which serum IgE levels were estimated in patients presenting with 
wheezing and to identify the potential cases of asthma on the basis of 
raised IgE levels. In this study, they found that mean serum IgE was 
significantly higher in asthma patients (p <0.001). In conclusion, they 
reported that determination of serum IgE may be of value in identifying 
those children presenting with first attack of wheezing  who may develop 
asthma in future and these cases needs long term follow up for of 
conclusion. 
          In a study done by Saha O.K, Modaka Batabayal S.K., Choudhari 
D.K,Maitra S.B. et al about clinical significance of IgE in bronchial 
asthma, total mean serum IgE
22
 levels of 63 patients, suffering from 
bronchial asthma and 64 control subjects were estimated. Mean serum 
IgE level of patients and control subjects was 643-1125 I U/ml and   10-
100U/ml respectively.  
PULMONARY FUNCTION TESTS 
23
: 
 
John Hutchison, a surgeon recognised that the volume of air that 
can be exhaled from fully inflated lungs is a power indicator of longevity. 
  
 
He invented the spirometer to measure what he called vital capacity, ie, 
capacity to live. Later concept of timed vital capacity, known as forced 
expiratory volume in one second (FEV1) was added. Since then 
pulmonary function tests has become important aspect of evaluation of 
respiratory diseases. 
 
Clinical  use of  spirometry  are 
• To make a diagnosis based on lung function  
 
• Assess patients treatment response. 
 
• Pre operative pulmonary evaluation 
 
• Detection of pulmonary function abnormality in predisposed 
individuals, eg: occupational exposure, neuromuscular, chest wall 
or upper airway disorders 
• Most important component in successful  pulmonary function 
testing is a well motivated and enthusiastic technician.He should  
also  be well trained and experienced 
• At least three repeat testing is necessary is important for proper 
interpretation of results. 
CONTRAINDICATIONS OF SPIROMETRY 
• Post  myocardial infarction upto one month 
• Chest/abdominal colic 
• Cognitive impairment 
  
 
Types  of  spirometers of  2 types 
1. Volume displacement spirometers 
2. Flow sensing spirometers 
      Flow sensing spirometers are mostly used as they are portable and 
easy to maintain. They are either pneumotach based or turbine based. 
 
Figure 18: Performing  Spirometry 
 
Expiratory manoeuvre 
• Take a full deep,breathe away from spirometer 
• Hold the mouth piece between lips to create a good seal 
• Fastly and hardly expire  until no breathe is left 
Expiratory and inspiratory manuevre 
• Hold the mouth piece between the lips to get a good seal 
  
 
• Breathe in and out for 2-3 tidal breaths 
• Expire as fast and as hard as possible for as long as possible until 
no breathe is left 
• Inspire rapidly to a maximum capacity 
 Spirometry should be repeated again 15-30 minutes after 
administration of short acting beta agonist, 200-400mcg of salbutamol,to 
check for bronchodilator reversibility. 
 
 
Figure  19 : How a spirometry works? 
  
 
        A spirometer records movement of lid,which moves upwards when 
patient inspires and downwards when expires. It can measure tidal 
volume,inspiratory reserve volume,inspiratory capacity,expiratory reserve 
volume and vital capacity. 
Recording Spirometry
23
 
Recorded both graphically and numerically 
Graphically it is recorded as  
• Volume versus time (Spirogram) 
• Flow rate versus volume 
Flow volume curve when only expiratory flow is recorded   Flow volume  
loop when inspiratory flow is also recorded. 
 
Figure   20 : Lung capacities 
  
 
1. Tidal  volume – 500ml, It is the air that moves into the lung with each 
normal inspiration  or the volume of air that moves out of the lung with 
each normal expiration. 
2. Inspiratory reserve volume – 3300 ml, The air inspired with a 
maximal inspiratory effort in excess of tidal volume. 
3.Expiratory reserve volume-1000 ml,Air expelled with a maximal 
expiratory effort in excess of tidal volume. 
4.Residual  volume– 1200 ml,Amount o air remaining in the lungs even 
after forced expiration 
 
5.Inspiratory capacity- TV+ IRV, 3800 ml,Total amount of air that can 
be  breathed  in. 
6.Vital capacity-IC+ERV,4800 ml,Maximum amount of air that can be 
expelled out forcefully after a maximal deep inspiration. 
7.Functional residual capacity-2200ml,Volume of air remaining in the 
lung after normal expiration. 
8.Total lung capacity-6000 ml,Amount of air present in the lung after 
maximal  inspiration.Maximum volume to which lungs can be 
expanded
23
. 
  
 
Respiratory minute volume-6litres/min 
• Alveolar ventilation -4.2litres/min, Amount of air utilized for 
gaseous exchange every minute, 
• Alveolar ventillatin=(Tidal volume – Dead space volume)x 
Respiratory rate 
• FEV1-Forced expiratory volume in 1
st
 second, It is the fraction of 
vital capacity expired during 1
st
 second first second of forced 
expiration 
23
. 
Also known as timed vital capacity. 
In normal person FEV1 is 75 to 85%, FEV1 is more sensitive than 
vital capacity because in the early stages of many chronic diseases(eg-
emphysema),vital capacity may remain normal, but the FEV1 begins to 
fall from very beginning. 
Resistance to small airways is best measured by maximum mid 
expiratory flow rate followed by FEV1
19
.  In early obstructive disease 
which originates in small airways FEV1/FVC may be normal but FEF 25-
75%. Maximum  midexpiratory flow rate is the average expiratory flow 
rate during the middle  50% of the vital capacity. It is also called FEF25-
75%.  
Hallmark of obstructive lung diseases is  a decrease in FEV1/FVC. 
 
  
 
Spirometry in asthma 
     Asthma is characterised by obstructive abnormality with good 
bronchodilator  reversal. Assessment of asthma severity (Global Initiative 
On Asthma-GINA guidelines) is necessary for recommended step care 
approach to management of asthma. 
       Asthma severity based on spirometry is classified as follows 
  
Severity 
1.Intermittent                 ≥ 80% 
2.Mild persistent           ≥ 80% 
3.Moderate persistent   60-80% 
4.Severe  persistent       ≤ 60% 
 
Spirometry in restrictive abnormality 
                Restrictive abnormality occurs due to chest wall 
diseases,pleural diseases, parenchymal and interstitial lung 
diseases.Characteristic pattern of restrictive abnormality is reduced forced 
vital capacity 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 21: Flow volume loop in different airway pathologies 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 22  : Comparison of spirometry - normal patient (A)and ,  
restrictive defect (B), obstructive defect (C). 
 
 
 
 
 
 
  
 
 
 
DIAGNOSIS OF ASTHMA 
 
 
 
 
Figure 23: Spirometry in asthma-Pre and post bronchodilator 
reversibility 
 
 
 
 
 
  
 
 
 
 
 
Figure 24  : Classification of asthma severity 
 
 
 
 
 
 
 
  
 
MANAGEMENT OF ASTHMA 
 
Successful management of the asthmatic patient requires an appreciation 
of two basic principles. 
• First, asthma  shows considerable heterogeneity  
• In each patient, symptom  severity may vary . Few may  have  a  
remission  during adolescence, only to have  them recur with even 
greater severity later in life.Intercurrent excacerbations  that arise 
due to seasonal  allergies or infection  are common  inasthma.  
• Thus, the patientshould be monitored regularly, and treatment 
should be modified on an ongoing basis to meet the patient’s 
current needs. 
 
 
AIMS OF ASTHMA THERAPY 
 
 Minimal or no chronic symptoms,including nocturnal 
 
 Minimal excacerbations 
 
 No emergency visits 
 
 Minimal use of required beta 2 agonist 
 
 No limitations on activities including exercise 
 
 Near normal PEF 
 
 Peak expiratory flow circadian variation <20% 
 
 
 
 
  
 
CHRONIC STABLE ASTHMA 
 
Nonpharmacologic Therapy 
 
 Patient Education 
 
• Counselling the patient about the disease, its nature and risk factors 
and  environmental control programs are effective in reducing  
morbidity as proven by many studies, but additional research is 
needed to decide which methods are the most effective and which  
groups of patients  are benefitted the most. 
 
• Improving  patient understanding of the disease and its 
management and, thereby improving patient compliance to 
treatment is the aim. 
 
• Another aim is  engaging  patient in self management practices, 
especially in terms of identifying and avoiding asthma triggers and 
recognizing and treating excacerbations of asthma in their earliest 
stages. 
 
 
• Result in better control and decreased emergencies and 
hospitalizations due to asthma. The success of  education programs 
is, to a large extent, dependent on their format 
 
  
 
• Personal contact with a physician  is considered superior  to 
providing  either audiovisual or written materials 
 
Enquiry into  over 200 asthma deaths in a study in United kingdom 
has proven that risk factors, medical management and patients 
behavioural and psychosocial factors were associated with fatal and near 
fatal events in asthma. Most deaths occurred before hospitalisation. Most 
patients who died had severe asthma, but a few also suffered from mild to 
moderate background disease. Most deaths occurred in inadequately 
monitored and those who were not on regular drugs. 
Adverse behavioural or psychosocial factors 
 
 Non compliance with treatment on monitoring 
 
 Failure to attend clinic appointments 
 
 Self discharge from hospital 
 
 Depression, psychosis or other illness 
 
 Alcohol or other substance abuse 
 
 Obesity 
 
 Learning difficulties 
 
 Employment problems 
 
 Income problems 
 
 Childhood abuse 
 
 Social isolation 
 
  
 
All patients having severe asthma should have an agreed written 
action plan ,doing regular pulmonary function tests ,regular checking of 
inhaler technique and compliance. 
 
 
 Environmental Measures 
 
• Another important part of the management plan for all asthmatics 
is environmental measures 
 
• Avoidance of air borne allergens, viral respiratory pathogens, air 
pollutants, and certain drugs can prevent exacerbations, reduce the 
need for drug treatment 
 
• Avoidance of factors that may contribute to longer-term, airway 
inflammation responsible for abnormal airway responsiveness.  
 
• Allergens from house dust mites, cockroaches, moulds, and pets, 
particularly cats and dogs, have been associated with asthma. 
  
PHARMACOLOGICAL MEASURES 
 
BRONCHODILATORS 
• Act primarily on  smooth muscles of airways   
 
 
•  Provide fast relief  but not anti inflammatory  
.  
 
  
 
• 3 classes of bronchodilators are used:  
       β2 -ADRENERGIC AGONISTS 
 
• They activate  2 adrenergic receptors seen in airways. 
 
Mechanism of action 
• Its primary action is relaxation of both proximal and distal  airway  
smooth muscles preventing bronchoconstriction. 
• Inhibition of mast cell mediator release 
• Inhibition of plasma exudation and airway edema 
• Increased mucociliary  clearance 
• Increased mucus secretion 
• Decreased cough 
 
• No effect on chronic inflammation Clinical use 
 
• To decrease side effects, they are given by inhalation 
 
• Short acting beta agonists  like terbutaline and albuterol act for 
about six hours. It has faster  action, so effective for symptom 
relief. 
• SABAs  can be given via  a  nebuliser  or  an  inhaler 
• Drug which act on long acting  beta2 receptors  for example, 
formeterol  act for around half a day duration. It can be  inhaled  
two times a  day 
 
  
 
• LABAs when combined with ICS allow reduced dose if ICS to be 
used 
Side effects 
• Most common are muscle  tremor and palpitations common in 
elderly individuals 
• Slight hypokalemia can occur 
• Tolerance is a main issue with chronic use  ,when  beta receptors 
are downregulated,but bronchodilator effect is not reduced  
• But mast rapidly develop tolerance,and this is reduced by 
simultaneous use of glucocorticoids 
 
ANTICHOLINERGICS 
 
• Muscarinic receptor antagonists like ipratropium bromide are 
useful in preventing cholinergic nerve induced 
bronchoconstriction and mucus secretion 
 
• As they inhibit only cholinergic pathway they are they are less 
effective than beta agonists 
 
• High doses can be given via nebuliser but only after beta 
agonists as they have slower onset of action 
 
• Systemic absorption is minimal,so minimal adverse effects. 
 
 
 
 
  
 
THEOPHYLLINE 
• Years before  it was given for dilatation of airways orally 
 
•  Phosphodiesterases is inhibited in muscle cells, thereby 
increasing CAMP and causing bronchodilatation. 
 
Clinical use 
 
• Orally given as slow release preparation. 
 
• IV Aminophylline which is a soluble salt of theophylline was 
initially used for treatment of severe asthma, but now replaced 
by high dose of inhaled SABAs, as they are more effective with 
few side effects. 
 
• Now mainly used as an adjunctive therapy 
Side effects 
• Most common side effects are nausea, vomiting,headaches and 
is due to phosphodiesterase inhibition 
 
• At higher doses, arrhythmias, epiplepsy can occur. 
 
• Adverse effects are directly proportional to plasma concentration 
and is rarely seen below 10 mg/dl plasma concentration 
 
• Drugs like erythromycin and allopurinol that metabolize 
cytochrome P450 should be used with caution as theophylline is 
metabolized in liver by same pathway and so plasma 
cpncentrations can be elevated
25
. 
 
• Enzyme inhibitors like cimetidine congestive cardiac 
failure,liver disease can lead to decreased clearance of drug 
  
 
 
Figure 25 : Factors affecting theophylline clearance 
CONTROLLER THERAPIES 
Inhaled Corticosteroids 
• The  most useful controllers for asthma are inhaled corticosteroids, 
and their early use  revolutionized asthma therapy 
24
. 
 
Mode of Action 
• They are most effective anti inflammatory agents,reducing 
inflammatory cell number. 
 
• They reduce number of sputum and airway eosinophils,number of 
mast cells and activated  T lymphocytes 
  
 
 
 
 
     Figure  26 : pharmacokinetics of inhaled corticosteroids 
 
SIDE EFFECTS OF STEROIDS 
 
• Oral candidiasis 
 
•  Dysphonia 
 
• At  increased doses reduce both  plasma  and  urine  cortisol 
 
 
 
  
 
 
 
Figure 27 : Step wise treatment approach 
 
Step Wise Treatment Approach 
 
Step 1-Using inhaled SABAs 
 
Step 2-Introducing ICS in low dose 
 
• To be added in any patient who has developed asthma 
excacerbation in last 2 yrs 
• Uses inhaled beta agonists 3 times/week or more 
• Becomes symptomatic 3 times/week or more 
• Night awakenings due to asthma once per week 
 
 
  
 
 Starting dose is 400 µg beclometasone dipropionate (BDP) 
or budesonide(bud)equivalent per day in adults. BDP and 
BUD are approximately equivalent in clinical practice, 
although there may be variations with different delivery 
devices 
25
.  
 Fluticasone and mometasone provide equal clinical activity 
to BDP/BUD at half the dosage. 
 
Step 3 –Add on therapy  
 
• Long-acting β2-agonists (LABAs), such as salmeterol and formoterol 
(duration of action-12 hours) are the first choice 
 
• The first trial put forward  the concept of LABA combination with 
ICS as inhalation therapy was FACET. 
 
• Addition of formeterol to budesonide was more efficous than doubling 
budesonide dose according to the trial. 
 
• At present, the use of single inhaler therapy as both rescue medication 
and for controller therapy is propagated by the SMART Approach 
 
• According to SMART
26
 approach, Formeterol has a dose response 
relationship than salmeterol, better bronchodilatation is attained with 
increasing dose of  formeterol than salmeterol. 
 
• Formeterol also has a faster onset of action,is a more dynamic drug 
than salmeterol and so SMART has a place in GINA guidelines. 
 
  
 
• ICS-LABA combinations has undergone a change from FACET to 
Adjustable maintanence dosing(AMD) to the SMART approach 
making asthma control goals easy to achieve.  
 
• AMD and SMART suggest a single inhaler therapy for both 
prevention and relief –AMD  following step up combination therapy 
for few days till control, while SMART suggests combination inhaler 
therapy for both prevention and relief 
26
. 
 
• Indacaterol is a once daily LABA, which is newly introduced. 
 
• In future, Mometasone and indacaterol combination if approved could 
be a milestone in a once daily medication for long term asthma relief. 
 
• Improve asthma control, decrease the frequency and severity of 
exacerbations when compared to increasing the dose of ICS alone. 
 
Step 4- Addition of a 4th drug when the response on moderate dose 
of inhaled steroid and add-on therapy is poor 
 
• Increase dose of ICS to to 2000 µg BDP/BUD a day 
 
Step 5:  Use of Oral Steroids 
• Oral prednisolone in the lowest dose as a single morning dose can be 
started
28
 
 
• In patients on long term steroids to prevent 
osteoporosis,bisphosphonates can be given. 
 
• Steroid-sparing therapies such as methotrexate, cyclosporine, iv 
gamma  globulins  can  cause significant side-effects. 
 
 
  
 
Anti-IgE Monoclonal Antibodies 
 
• Omalizumab rapidly decreases serum IgE and is useful as adjunctive 
therapy 
• Recombinant,humanised monoclonal antibody. 
• It binds to portion of Ig E which recognises receptors on surface of 
mast cells, basophils and dendritic cells. Binding of Ig E to receptors 
is prevented blocking release. 
• Available as sterile, white, reconstituted  with water. 
• It was recommended by GINA at stage 5, showing moderate results 
when used as add on therapy either ICS and LABA combination. 
• Disadvantage-High cost and less cost benefit ratio. 
• Dosage is based on Serum Ig E level and weight of patient. It is given 
to those having serum Ig E between 30-700 IU/ml, showing 
sensitisation to air borne allergens like dust mites, moulds, 
cockroaches. 
• Patients are treated for around 5 months for showing positive result 
without any adverse effect  
•  No  significant side effects 
 
• Anaphylaxis is very rarely seen. 
 
Anti interleukin 13 therapy 
 
 IL-13, a cytokine of type 2 helper T cells, involved in asthma 
development 
31
. 
 
 Lebrikizumab, newly developed monoclonal antibody to  
IL-13, binds to it and inhibits its action. 
 
 
Step-down therapy  
 
       When disease  is controlled, reducing  inhaled /or oral steroid dose  
should be initiated and maintained at lowest dose at which good control is 
achieved 
  
 
 
 
 
 
 
.
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28 : GINA Guidelines 2008 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 29 : Levels of asthma control according to GINA 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 30 (a) :Treatment guidelines (GINA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure  30 (b) :Treatment guidelines (GINA) 
 
 
  
 
 
 
Figure   31 : Treatment regimen based on severity 
 
1. Mild Intermittent Asthma
29
 
• Inhaled beta agonists usually provide relief 
2. Mild Persistent Asthma 
• Low-dose inhaled glucocorticoids are the preferred medications. 
 
• Leukotriene inhibitors, cromolyn, or nedocromil are alternatives 
 
3.Moderate Persistent Asthma 
 
• Low-dose inhaled steroidscombined with a long acting beta 
agonist or medium-dose inhaled steroids is the preferred therapy 
 
 
 
 
 
  
 
 
4. Severe persistent asthma 
 
• Asthma in which symptoms persist ,despite treatment with high-
dose inhaled glucocorticoids and additional therapy with long-
acting beta agonists, leukotriene pathway inhibitors, or 
theophylline. 
 
• Poor drug compliance  or  exposure to environmental factors or 
drugs such as aspirin or beta blockers are frequent causes.So 
detailed probe into  these factors is indicated before the start of 
additional drug therapy. 
 
• Options include  
 
a) Increasing the dose of inhaled glucocorticoids 
 
b) Adding sustained-release theophylline or a leukotriene 
modifier in patients already taking inhaled glucocorticoids 
and LABAs
30
 
 
c) adding a  LABA to the regimen for patients already taking 
inhaled  steroids and theophylline or a leukotriene modifier 
 
d) Anti IgE antibody omalizumab has  been  shown  to be 
useful 
 
 
  
 
 
Figure 32  : Symptomatology,spirometry results and 
management based on severity. 
 
Immunotherapy in asthma 
 
• Allergen immunotherapy is found to be useful in selected patients     
with defined allergic triggers. Generally, patients having many 
allergic     triggers  benefit less  from immunotherapy than those 
having identified with a single trigger. 
  
 
 
• Patients with mild  or moderate persistent asthma who arenot 
adequately controlled with inhaled drugs can beconsidered for 
immunotherapy. 
 
• Those with concomitantnasal symptoms  are benefitted the most. 
 
• Although serious complications from immunotherapy are rare, they 
occurmore frequently in patients with asthma. 
• Incidence of adverse systemic reactions is very high, so patients 
whose FEV1 is less than 70 percent of predicted should be 
considered at high risk of complications from immunotherapy 
 
Treatment of Associated Conditions 
 
• Effective asthma treatment of asthma  needs  treatment of 
conditions that lead to aggravation of asthmatic symptoms 
31
 . 
 
• Asthma  can coexist with many disorders  that  affect  lung  
function. 
 
• Gastroesophageal reflux disease, obesity, and  chronic sinusitis  are 
the most commonly associated with poor  control of asthma 
 
 
 
 
 
 
  
 
Other Considerations 
 
• For acute asthma exacerbations, unless there is objective evidence 
of bacterial pneumonia or co-existing bacterial sinusitis, antibiotics 
are not indicated.  
 
• Oxygen therapy is needed to avoid hypoxia -oxygen saturation 
greater than or equal to 92 percent is to be maintained. 
 
• Oxygen should be titrated to the lowest dose needed as excessive 
oxygen concentrations can lead to CO2 retention and a respiratory 
acidosis in some patients 
31
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• Deep venous thrombosis is indicated for the hospitalized asthma 
patient. 
 
• As there is increased use of steroids, stress ulcer prophylaxis is 
also indicated. 
 
 
Special situations 
 
1.Asthma in Elderly 
 
 Side effects more common due to therapy like muscle tremor with 
beta agonists and increased systemic side effects with ICS. 
 Interactions with drugs and comorbidities frequent. 
 
 Chronic obstructive pulmonary disease may coexist 
 
  
 
 OCS trial may be beneficial in documenting steroid 
responsiveness. 
2. Pregnancy and asthma 
 
 1/3rd of asthmatics improve, 1/3 rd worsen and 1/3 rd remain 
same. 
 SABAs, ICS, and theophylline are safe. 
 
 Prednisone better than prednisolone as it cannot be converted to 
active prednisolone by fetal liver. 
 
 Breast feeding  is not contraindicated when on drugs. 
 
3. Smoking and asthma 
 
 Smoking affects anti-inflammatory action of steroids thereby 
increasing requirement for higher dose. 
 
 Vigorous smoking cessation should be followed 
 
 
4. Surgery and asthma 
 
 Adrenal suppression can occur in OCS treated patients and so 
increased dose of OCS prior to surgery is needed. 
 
 Poor wound healing and increased infection due to high dose of 
corticosteroid use may be a contraindication to surgery. 
 
 
 
 
 
 
  
 
MATERIALS AND METHODS 
 
Source of data 
 
The study was conducted among  patients who presented to 
Coimbatore medical college  medicine outpatient/pulmonary medicine 
outpatient department / those who got admitted in Coimbatore medical 
college hospital.  
 
Sample size 
100 
 
Study period 
 
       From August 2013 to August 2014. 
 
Study design 
 
       Observational clinical study 
 
Study population 
 
         Hundred patients who presented initially with wheeze and 
breathlessness  were included in the study. 
 
Inclusion criteria 
 
• Age group 18-60 years 
 
• Clinical features of bronchial asthma as per GINA Guidelines. 
 
• All cases of Bronchial Asthma of age group 18-60 years having  
proven airflow reversibility by Spirometry.  
  
 
• Patients willing to give written informed consent to participate in 
the study. 
Exclusion Criteria 
 
• Patients having on going or past history of tuberculosis ,chronic 
obstructive pulmonary disease  or  interstitial lung disease.  
 
• Any history of haemoptysis.  
 
• Those on oral corticosteroids prior to the study.  
 
• Congestive cardiac failure patients. 
 
• Evidence of infective exacerbation like  fever, purulent 
expectoration, raised leukocyte counts, specific growth of micro-
organisms in sputum culture. 
 
• Pregnant  females with asthma 
 
 
METHODOLOGY 
 
 Patients who attended hospital with complaints of 
wheeze and breathlessness,and associated symptoms like 
cough and nocturnal awakenings were included for the 
study. 
 Symptomatology and duration was recorded for all. 
 
 Spirometry was done and FEV1 and  PEF was measured both 
before and  twenty  minutes post nebulisation withsalbutamol.. 
  
 
 Asthma severity was analysed  by both  history and 
prebronchodilator  FEV1% of  Predicted . 
 According to latest GINA Guidelines,severity was also assessed 
as follows 
 
1. Controlled asthma –No day time symptoms(less than       
twice/week),No limitation of activities,No nocturnal symptoms or   
awakening,No need for rescue or reliever treatment(less than 
twice/week),Normal lung function tests, No excacerbations. 
 
2. Partially  controlled asthma- More than twice/week day time   
Symptoms, any limitation of activities, any nocturnal   
awakenings,reliever or rescue treatment more than twice/week. 
 
3. Uncontrolled asthma-3 or more features of partly controlled   
asthma present in any week,one in any week excacerbation. 
 
Method of data collection 
 
• Serum Ig E 
 
 
Venous clotted blood of 2 ml was used for measuring IgE levels using 
commercially available diagnostic ELISA kits.It is a solid phase enzyme 
linked immunosorbent assay based on sandwitch technique. 
 
 
 
  
 
• Absolute eosinophil Count 
 
Venous EDTA blood will be subjected to automated analyser for AEC 
and confirmed by peripheral smear. 
 
 
STATISTICAL  ANALYSIS 
 
All the information obtained from our study population was 
collected and recorded in master chart. Statistical significance was 
analysed  by Chi-square test and logistic regression analysis was 
performed with  SPSS  software to assess independent association of 
variables found to be significant in univariate analysis. 
 
 
Concept of  P value 
 
• If the P value is between 0.000 to 0.010, it is considered to be 
significant at level 1- Highly Significant 
 
• If the P value is between 0.011to 0.050,it is considered to be 
significant at level 5- Significant 
 
• If the P value is between 0.051-1.000,it is considered insignificant  
At level 5 -Not Significant 
 
 
 
 OBSERVATION AND ANALYSIS
 
TABLE 1.SEX DISTRIBUTION OF STUDY POPULATION
 
SEX
Male
Female
Total
 
CHART 1. SEX DISTRIBUTION OF STUDY 
 
In our study, the male to female ratio was 1:1.2 with males  constituting 
45% and females  constituting 55% of bronchial asthma cases.
 
 
 PERCENT 
 
 
45 
 
 
55 
 
 
100 
POPULATION
 
 
 
 
 
 
  
 
TABLE 2. AGE DISTRIBUTION OF STUDY POPULATION 
 
AGE(YEARS) PERCENTAGE 
18-25 18 
26-33 47 
34-41 31 
>41 4 
TOTAL 100 
 
CHART 2. AGE DISTRIBUTION OF STUDY POPULATION 
 
 
Most common age group in our study population  was 26-33 years 
 
0
5
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 TABLE 3. INCIDENCE OF ALLERGY
 
ALLERGY
DUST ALLERGY
FOOD ALLERGY
OTHERS 
NO SPECIFIC 
ALLERGY 
TOTAL 
 
CHART 3. INCIDENCE OF ALLERGY
 
 
Among 100 cases of bronchial asthma in this study, 79 had history of 
some allergy to dust or food or others.
 
 
 FREQUENCY PERCENTAGE
 50 50 
 2 2 
27 27 
21 21 
100 100 
 
 
 
 
 
 TABLE 4. ALLERGY AND  PREVALENCE
 
CHART 4. ALLERGY AND  PREVALENCE
Prevalence of asthma is more in patients with allergy in our 
0
5
10
15
20
25
30
MILD MODERATE
 MILD
WITH 
ALLERGY 
21
WITHOUT 
ALLERGY 
TOTAL 24
 
 
 
study population. 
 
 
SEVERE
WITH ALLERGY
WITHOUT ALLERGY
 MODERATE SEVERE 
Highly 
significant
 30 28 
3 14 4 
 44 32 
 
 
 
 
 
 
P Value 
0.002 
 
 
 
 TABLE 5. 
 
 
 
 
 
 
 
CHART 5. INCIDENCE OF FAMILY HISTORY
 
Family history was positive in 56% of cases in our study.
 
 
 
 
 
INCIDENCE
PERCENTAGE
 
 INCIDENCE OF FAMILY HISTORY
 YES NO 
 56 44 
 
 
 
 
 TABLE 6. FAMILY HISTORY AND SEVERITY
 
 MILD
YES 12 
NO 12 
TOTAL 24 
 
CHART 6. FAMILY HISTORY AND SEVERITY
 
• In our study population,56%  had  a  positive family history
 
• Among the 56% who had a positive family history,28% had severe,
16%  had moderate and 12% had mild asthma.P value was 
 
 OF ASTHMA
 MODERATE SEVERE 
 
 
 
 
P  Value  
   
16 28 
28 4 
44 32 
 OF ASTHMA
0.000
 
 
 
0.001 
 
 
 
 
1. 
 TABLE 7 .ASSOCIATION OF ASTHMA WITH VARIOUS CO 
 
 
 
 
 
 
 
 
CHART 7. ASSOCIATION 
Allergic rhinitis was the most common co morbid
condition associated
 
 
0
5
10
15
20
25
30
35
40
45
ALLERGIC  
RHINITIS
SINUSITIS
 
COMORBID 
CONDITIONS
 
ALLERGIC  RHINITIS
SINUSITIS 
ECZEMA 
GERD 
OBESITY 
NONE 
            TOTAL
 
MORBID CONDITIONS 
OF ASTHMA WITH VARIOUS  
COMORBID CONDITIONS 
 with bronchial asthma in our study.
ECZEMA GERD OBESITY NONE
 
 
PERCENTAGE 
 34 
7 
6 
4 
5 
44 
                      100 
 
 
 
  
 
TABLE 8 : COMORBID CONDITIONS AND SEVERITY 
 
CHART 8 : COMORBID CONDITIONS AND SEVERITY 
 
 
 
0
10
20
30
40
50
60
CASES WITH 
COMORBIDITIES
CASES WITH NO 
COMORBIDITIES
MILD
MODERATE
SEVERE
 
No.of 
cases 
Mild Moderate Severe 
 
 
 
 
 
 
P 
VALUE 
0.002 
With 
comorbid 
conditions 
56 11 23 22 
Without 
comorbid 
conditions 
44 13 21 10 
Total 
 
     100 24  44 
 
       32 
 
 
 TABLE 9. SEVERITY  ASSESSED BY LUNG SPIROMETRY
 
 
CHART 9. SEVERITY ASSESSED BY  LUNG SPIROMETRY
Asthma severity based on spirometry is classified as intermittent and 
mild persistent with FEV1
FEV160-80% P,and severe 
study,44% cases were moderate and 32%  wassevere.
SEVERITY
Mild 
Moderate 
Severe 
Total 
 
≥80% P, moderate persistent with 
persistent with  ≤ 60%P. In our 
 
 
 FREQUENCY PERCENTAGE
24 24 
44 44 
32 32 
100 100 
 
 
 
 
 
 TABLE 10 : SEVERITY ACCORDING TO 
SEVERITY
PARTLY 
CONTROLLED
UNCONTROLLED
 
 
CHART 10  : SEVERITY ACCORDING TO NEW GINA 
 
According to latest GINA guidelines,the severity of our cases were 
77% uncontrolled and 23% partially controlled.
 
 
 
 
NEW GINA
GUIDELINES 
 PERCENTAGE 
 
23 
 77 
GUIDELINES 
 
 
 
 TABLE 11 : ABSOLUTE EOSINOPHIL COUNT AND SEVERITY 
 
Absolute 
eosinophil 
count(cells/cu.m
m) 
Upto 440 
>440 
 
CHART 11 :  ABSOLUTE EOSINOPHIL COUNT AND SEVERITY 
 
OF ASTHMA 
MIL
D 
MODERAT
E 
SEVER
E 
24 40 12 
0 4 20 
OF ASTHMA 
 
 
 
 
 
 
P 
VALU
E 
0.001 
 
 TABLE 12. MEAN
 
SEVERITY
MILD
MODERATE
SEVERE
 
CHART 12 
 
Mean Ig E in the mild asthma patients was 271.50 IU/mL,in the 
moderate asthma group was 916.48IU/mL,and in the severe group 
 
 
 SERUM IgE AND SEVERITY
 Mean IgE(IU/ml) 
 271.50 
 916.48 
 1662.59 
: MEAN SERUM IgE AND SEVERITY
was 1662.59 IU/ml. 
 
 
 
 TABLE 13 : 
 
 
CHART 13 : 
Serum 
IgE(IU/ml) 
MILD
< 100 7
>100 17
 
SERUM  Ig E LEVELS AND SEVERITY
SERUM  Ig E LEVELS AND SEVERITY
 
 MODERATE SEVERE 
VALUE 
   
 
 
 1 0 
 43 32 
 
 
 
 
 
 
 
 
 
P  
 
0.001 
  
 
RESULTS 
• In our study common age group with bronchial asthma was 26-30 
years 
• Female sex predilection was seen in adults, with male to female  ratio 
of 1:1.2 
• In our study population,79%had history of allergy to dust,food or 
others and 21% had no history of allergy 
• 56% of study population had associated comorbid conditions.  
• Among the associated comorbid conditions, 34% had allergic rhinitis, 
7% had sinusitis, 6%had eczema, 4%had GERD,5% had obesity. 
• Allergic rhinitis was the most common assossiated  co morbid 
condition. 
• Severity of asthma had positive correlation with the occurance of co 
morbidities. (P Value 0.002) 
• In our study population,56% had a positive family history 
• Among the 56% who had a positive family history,28% had severe, 
16%  had moderate and 12% had mild asthma.P value was 0.000 
• Mean AEC in our study population was 423.08 cells/cu.mm. 
• Among  the 32% severe cases of bronchial asthma in the study, 20% 
had absolute eosinophil counts >440 cells/cu.mm, with  P Value 0.000 
showing high significance.  
• Among the moderate persistent group only 4% had AEC >440 
cells/cumm & in the mild persistent group none had AEC > 
440cells/cu.mm. 
• Among the 100 cases of bronchial asthma studied,mean Ig E in the 
mild asthma patients was 271.50 IU/mL, in the moderate asthma 
group was 916.48IU/mL, and in the severe group was 1662.59 IU/mL. 
 
  
 
• Among the 24 mild asthmatic patients, 17% had S.IgE >100 IU/mL 
and among the 44% moderate persistent patients, 43% had S.IgE >100 
IU/mL and 32% severe cases, all had S.Ig E >100 IU/mL . 
 
• P  Value was 0.000 showing high statistical significance between  
S.Ig E level and severity of asthma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
DISCUSSION 
In this section, we  are  comparing  the  results  of  our study with 
previous  studies conducted  and  their  results .This  was a study 
conducted in Coimbatore medical college hospital with 100 consecutive  
patients. The purpose of the study was to find out if there was any 
correlation between  absolute eosinophil count, serum Ig E levels and 
severity of  bronchial asthma also evaluated the patients for 
symptoms,risk factors, family history,and  comorbid conditions to assess 
its relation with asthma severity. 
TABLE : 14  
COMPARING SEX DISTRIBUTION WITH OTHER STUDIES 
 
 
 
 
 
 
 
 
 
 
 
• B.Leynaert et al studies have shown that asthma was 20% more 
frequent in females than in males over the age of 35 years. 
Incidence of nonallergic asthma was higher in females than in men 
throughout all reproductive age group. 
 
STUDY SEX 
PRESENT  STUDY F >M 
B.LEYNAERT ET AL F >M 
D.MARCO ET AL F >M 
       BAPNA ET AL F>M 
  
 
• Bapna et al  in  1998  reported that female sex show higher 
predilection than males  
• Studies  done by Kynyk Et al show that women are more likely to 
develop asthma and suffer from more mortality than 
men.Hormonal and genetic susceptibility both contribute to this 
change. 
• Studies by de Marco.R et al also show severe asthma is more 
predominant in women.During childhood, girls had a significantly 
lower risk of developing asthma than  boys (relative risk (RR): 
0.74 and 0.56 in the 0 to 5yr and 5 to 10 yr age, respectively). 
Around puberty, the risk was almost equal in the two sexes (RR = 
0.84). After puberty, the risk in women was always significantly 
higher than that in men (RR: 1.38 to 5.91). This pattern was 
consistent in all  16 countries studied from 1991 to 1993 . Women's 
greater susceptibility to asthma in early adulthood was at least 
partly, explained by their smaller airway calibre. 
ALLERGY AND ASTHMA SEVERITY 
• Prevalence of asthma is more in patients with allergy in our  
 study population. 
• According  to studies by  Lebowitz et al  and   Peat  et al,  the role 
played by atopy contributes to the highest risk. 
 
  
 
FAMILY HISTORY AND ASTHMA SEVERITY 
• In our study population,56%  had  a  positive family history. 
Among the 56% who had a positive family history,28% had 
severe,16%  had moderate and 12% had mild asthma. 
• P value was 0.001 showing high statistical significance. 
• Results of a study done by Parisa Davoodi,P.A Mahesh,and Nallur 
B.Ramachandra indicated a positive association between having a 
family history of asthma and higher socio-economic status. Family 
history of asthma and a topy have been introduced as the strongest 
risk factors in adult asthma 
TABLE : 15 
COMPARING FAMILY HISTORY AND ASTHMA 
SEVERITY WITH OTHER STUDIES  
 
 
 
 
 
 
 
 
 
 
PRESENT STUDY PERCENTAGE 
PRESENT  STUDY 56% 
PARISA DAVOODI et al  61% 
  
 
ASTHMA AND ASSOCIATED COMORBIDITIES 
 
• In our study, 56%  had associated comorbidities of which allergic 
rhinitis constituted 34 cases, others were sinusitis, eczema, obesity 
and GERD. Comorbidities had positive correlation with severity of 
bronchial asthma as assessed by spirometry which were similar to 
studies by de Groot et al and Andrea G Gershon 
 
• Studies by Louis Philippe Boulet,Marie Eve Boulay ,report that 
asthma in adults is most commonly associated with comorbidities 
such as rhinitis, sinusitis, obesity, obstructive sleep apnea and  
gastro-oesophageal reflux disease  which is  similar to 
comorbidities in our  study population. 
 
• In a study done by de Groot et al ,the comorbidity associated with 
AR is high in adult age group and in children 
 
• In a study done to assess the burden of co morbidities in asthma 
individuals by Andrea S Gershon, Teresa To, Jun Guan in 
Ontario,Canada among 12 million residents,obesity,depression and 
allergic rhinitis were associated co morbidities. 
 
 
  
 
• Soriano et al. estimated the prevalence of comorbid diseases from 
an administrative data-based study including 7931 patients with 
asthma and matched controls.The most prevalent associated 
condition in adult asthmatic patients was time-limited minor 
infections while others with a high impact and/or high prevalence 
were depression, hypertension, diabetes, ischemic heart disease, 
degenerative joint disease, cardiac arrhythmia,and COPD. A total 
of 60% of adult asthma patients had at least one condition, and 
12% had three or more 
TABLE : 16 
COMPARING ASSOCIATED COMORDITIES WITH 
OTHER STUDIES 
 
STUDY ASSOCIATED 
COMORDITIES 
PERCEN 
TAGE 
CORRELATION  
WITH 
SEVERITY 
Present Study Allergic rhinitis ,Obesity, 
Sinusitis, Eczema, GERD 
56 Positive 
Soriano et al  Allergic Rhinitis, Hypertension, 
Ischemic heart disease, 
Depression 
60 Positive 
deGroot et al  Allergic Rhinitis 51 Positive 
Andrea S 
Gershon 
Allergic Rhinitis 54 Positive 
 
 
  
 
TABLE : 17 
COMPARING MEAN SERUM Ig E AND SEVERITY  WITH 
OTHER STUDIES 
 
Among the 24 mild asthmatic patients, 17 % had S.IgE >100(IU/Ml) and 
among the 44% moderate persistent asthma patients,43% had S.IgE >100 
( IU/ml)and 32% severe cases, all had S.Ig E >100.Severity of asthma 
statistically  correlates with the serum level of Ig E. 
 
• Our present  study shows that suggest that S. IgE levels increase 
with severity  which is similar to studies by Janeway et al  and  
Kovac et al. 
 
STUDY 
MEAN Ig E ( IU/ml) 
 
    MILD           MODERATE     SEVERE 
 
 
P VALUE 
PRESENT 
STUDY 
271.50 916.48 1662.59 0.000 
SRIKANTAIAH 
ET AL 
250 846 1045.32  
JANEWAY ET 
AL 
        304.6         882.4     1420.48  
  
 
• Burrow et al in 1982 and Castorline et al in 1983 first described 
role of S.Ig E and air flow obstruction in asthma 
 
• In our  study, mean serum Ig E in  mild, moderate and 
severepersistent cases  was  271.50, 916 48, 1662.59 which is 
similar to the study by Srikantaiah et al 
 
• Studies done by Kornelija Kovac et al in children aged 5-15 years 
showed that asthmatic children have elevated S.IgE             
concentration.  Asthmatic children with higher asthma severity 
have a  higher concentration of both Total Ig E (>288 IU/mL) and 
specific Ig E  to Dermatophagoides pteronyssinus (>44.1IU/ml) 
TABLE : 18 
COMPARING ABSOLUTE EOSINOPHIL COUNT (AEC) AND 
SEVERITY OF ASTHMA WITH OTHER STUDIES  
STUDY 
      MEAN AEC 
(cells/cu.mm) 
CORRELATION 
WITH SEVERITY 
PRESENT STUDY 423.08 
P VALUE O.OO1 
Positive 
MILAAT ET AL 581.7 Positive 
KOSHAK ET AL 
 
480.28 Positive 
 
  
 
• In our study among the 32 severe asthma patients, 20 had raised 
AEC with high statistical significance similar to the study by 
Koshak et al and Kamfar et al. 
 
• In a study done by Koshak et al ,60 asthmatics aged 15 to 70 years, 
of which 68.3% were female, were studied. Severity levels differed 
between the two assessment methods in 45% of the cases and 
showed a predominance of the moderate persistent type. Absolute 
eosinophil count ranged between 22 and 2470 cells/mm3 and 
eosinophilia was found in 50% of the cases. AEC showed a high 
positive correlation with increased asthma severity level assessed 
by history alone. 
 
•  In a study by Kamfar HZ ,Milaat et al,i n asthma patients,the AEC 
for the groups ranged between 10 and 2100 cells/mm3 (mean = 
581.7 cells) and showed a very significant positive correlation with 
increased asthma severity ( p<0.001). A high linear trend of  AEC 
within each clinical group was found ( p<0.0001), and the means 
among each group also showed a significant increase as asthma 
severity level increased ( p<0.001). The study documents a 
significant positive correlation between the clinical severity of 
bronchial asthma and eosinophil counts. Authors advocate the use 
of this simple and sensitive laboratory  test  as significant adjunct 
objective technique in the assessment of asthma severity and 
management. 
 
 
 
  
 
SUMMARY 
 This present study is an observational clinical study which analysed 
the correlation of serum immunoglobulin E levels and  absolute 
eosinophil count with the severity of bronchial asthma. 
 Study was conducted during a period of one year from   August 2013 
to August 2014. It involved 100 patients which were randomly 
selected from among outpatients and inpatients presenting to 
Coimbatore medical college hospital. 
 Relevant history and physical findings including symptoms were 
recorded. 
 Routine haematological, biochemical investigations, Chest X ray  
were done. 
 Spirometry was done in all patients and  FEV1 and  PEF  was  
measured both before and  20 minutes after giving nebulised 
salbutamol. Post  bronchodilator  reversibility of 12%  or  more  was  
taken  as criteria for  diagnosis of asthma. 
 Severity of asthma  was  assessed  by both  history and 
prebronchodilator  FEV1%  Predicted values. 
 Absolute eosinophil count and serum Ig E was assessed  in all patients 
of each severity group. 
 Among 100 patients, 55 were females and 45 were males. 
  
 
 Most common age group in our study population was 26-32 years 
,Range 18-48 years 
 56 among 100 had positive family history and there was positive 
correlation with family history and asthma severity. 
 Most common risk factor in the study population  was  atopy and the 
most common associated comorbid condition was allergic rhinitis 
 Other comorbidies in the study population were eczema, sinusitis, 
obesity and gastroesophagal reflex disease. 
 Asthma comorbidity has a strong association with the severity of 
asthma in our study population((P Value <0.01) 
 Positive correlation between absolute eosinophil count and severity of 
asthma was statistically significant. (P Value <0.01) 
 Serum immunoglobulin E levels also had positive correlation with 
severity of asthma which was statistically significant.(P value<0.01) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CONCLUSION 
 Based on our present study it was concluded that 
 Family history has a strong association with the disease and 
severity. 
 
 Asthma was also associated with comorbidities like allergic 
rhinitis,obesity,gastroesophagal reflex disease. 
 
 Comorbidity by the disease  has adverse impact on people’s health 
and health  care system. Focusing to tackle  such comorbidities is 
also crucial. 
 
 Asthma comorbidity has a strong association with the severity of 
asthma 
 
 Absolute eosinophil count has a definite positive correlation with 
asthma severity in the severe persistent asthma group.  
 
 Mean serum Ig E in  mild, moderate and severe persistent cases  
was  271.50 ,916.48,1662.59 IU/mL with positive correlation. 
 
 Our present study advocates the possible supplementation of 
absolute eosinophil count  and serum immunoglobulin E levels as 
another objective parameter that can  help in selecting the 
appropriate severity level in asthmatics. 
 
 Estimation of serum Ig E in diagnosed case of asthma gains 
importance with increasing severity based on clinical grading. 
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PROFORMA 
Name : 
 
 
Age: 
 
 
Sex (M/F):                      Occupation: 
 
 
Address:  
 
 
Presenting complaints: 
 
 
 
History of presenting complaints: 
 
 
a) Cough: 
 
• Frequency 
 
• Severity 
 
• Duration 
 
• Aggravating Factors 
 
• Relieving Factors 
 
b) Wheezing 
 
• Frequency- Daily/once a month /2-3 episodes yr/More frequent 
 
• No of days attack usually last-1-2 days/week or more than 1 
wk 
• Relieving factors -subsides on its own or medications or 
nebulisation 
 
  
 
C) Sneezing: Yes/ No 
 
• Diurnal variation- early morning/ night 
 
• Sleep- good/ occasionally disturbed/frequently disturbed 
 
• Work/College absence-Days/ weeks 
 
d) History of hospitalization: Yes / No 
 
• Duration of stay 
 
• Age of admission 
 
• Management- antibiotics/ antihistamines/nebu]isation/don’t know 
 
 
e)History of pneumonia: Yes / No 
 
X-ray proven - Yes /No 
 
f) History of TB: - Yes/ No 
 
• Any history of long standing cough/weight 1oss- yes/no 
 
• Evening rise of temperature/night sweats 
 
g) History of Allergy: Yes / No 
 
• Dust/food/othersetc 
 
Family history: 
 
• H/o allergy in family: 
 
• Bronchial asthma/urticarial/dermatitis/eczema  
 
• Relation to patient: 
 
Father/ mother/sibling/grand parent 
 
• Any other diseases in family 
 
  
 
Personal history: 
 
a) Allergy to food items 
 
     Milk/banana/vegetables 
 
 
b) Drugs 
 
      Aspirin/pencillin 
 
 
GENERAL EXAMINATION 
 
Built 
 
     Poor/moderate/well built 
 
Nourishment 
 
Poor, moderate/well nourishment 
 
Pallor/cyanosis/clubbing/lymphadenopathy 
 
Vital signs: 
 
Pulse 
 
BP 
 
Anthropometry: 
 
Weight 
 
Height 
 
SYSTEMIC EXAMINATION.: 
 
 
 
 
 
 
 
 
  
 
RESPIRATORY SYSTEM: 
 
Inspection: 
 
• Shape of chest- symmetrical/asymmetrical 
 
 
• Deformity –yes/ no 
 
• Accessory muscles of action- yes/no 
 
Pa1pation: 
 
 Trachea 
   
 Movement of chest wall- symmetrical/asymmetrical 
 
 Percussion 
 
 Hyper resonant/impaired/dull note 
 
 Auscultation 
 
 Rhonchi/ wheeze/ crepitation /others 
 
CVS: 
 
Heart sounds 
 
CNS: 
 
Cranial nerves 
 
Motor system 
 
Reflexes 
 
Per abdomen: 
 
 
 
 
 
  
 
Investigations: 
 
CBC 
 
Hb 
 
TC 
 
DC 
 
ESR 
 
AEC 
 
Chest X ray 
 
Serum Ig E 
 
Lung Spirometry 
 
Conclusion: 
 
Severity of asthma: 
 
Mild persistent 
 
Moderate persistent 
 
Severe persistent 
 
Planned treatment: 
 
Follow up: 
 
 
 
 
 
 
 
 
 
  
 
INFORMED CONSENT 
DEPARTMENT OF GENERAL MEDICINE 
                            COIMBATORE MEDICAL COLLEGE 
 
Principal Investigator   :  
Research Guide: 
Organisation: 
Informed Consent: 
Yourself , Mr/Mrs/Ms………are being asked to participate in the 
research study title “Correlation of serum immunoglobulin E levels and 
absolute eosinophil count with severity of bronchial asthma as assessed 
by lung spirometry ’’ Coimbatore Medical College hospital conducted by 
Dr.PriyaSeeraj,Post graduate in the Department of General 
Medicine,Coimbatore Medical College.You satisfy eligibility as per the 
inclusion criteria.You may ask any question before agreeing to 
participate. 
 
Research Being done: 
A STUDY ON CORRELATION OF SERUM IMMUNOGLOBULIN  E  
LEVELS AND ABSOLUTE EOSINOPHIL COUNT WITH SEVERITY 
OF BRONCHIAL ASTHMA AS ASSESSED BY LUNG 
SPIROMETRY 
 
 
 
  
 
Procedures involved 
Detailed history with clinical examination 
Routine haematological tests 
Chest Xray 
Serum Immunoglobulin E 
Absolute eosinophil count 
 
Decline from participation 
You have the option to decline from  participation in the study existing 
protocol for your condition 
Privacy and  Confidentiality 
Privacy of individuals will be respectedand any information about you or 
provided by you will be strictly confidential. 
Authorization to publish results 
Results of the study may be for scientific purposes and or presented to 
scientific groups,however you will not be identified. 
 
 
 
 
 
 
 
  
 
Statement of Consent 
     I volunteer and consent to participate in the study.I have read the 
consent or it has been read to me.The study has been fully explained to 
me and  I may ask questions at any time. 
 
 
 
……………………                                                  …………………….. 
Signature/Left thumb impression                                       Date 
(Volunteer) 
 
 
…………………….                                        ……………………… 
Signature of witness                                                            Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Key  To Master chart 
  Sex  
M-Male 
 F-Female 
Sex Code 
            Male-1 
            Female-2 
AH-Allergy history 
 DA-Dust  allergy,FA-Food allergy,N-No specificallergy,O–Others 
FH-Family history 
          Y-Yes 
N-No 
CM-Associated comorbid condition 
AR-Allergic rhinitis 
       S- Sinusitis 
E-Eczema 
GE-Gastro esophagal reflex disease 
       O-Obesity 
       N-None 
       S-Symptoms 
W-Wheeze,D-Dyspnea,NA-Nocturnal Awakenings,C-Cough 
F/wk-Frequency of need for reliever treatment/week 
FEV1%P -Forced expiratory volume in 1 st sec %Predicted 
Pre bro-Prebronchhodilator 
 Post bro-Postbronchodilator 
  
 
Rev%- Reversibility % postbronchodilator therapy 
S.Ig E-Serum immunoglobulin E 
AEC-Absolute eosinophil count 
G-Grade according to GINA(Global initiative for asthma guidelines) 
UC-Uncontrolled 
PC-Partly controlled 
       C-Controlled 
Severity 
        M-Mild persistent 
        Mo-Moderate persistent 
        S-Severe persistent 
 
 
 
 
 
 
 
 
 
  
 
xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :        taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jtj; 
Jiwapy; gl;l nkw;gog;g[ gapYk; khzth;; nkw;bfhs;Sk;  ;;;
"!;ignuhbkl;hp; bfhz;L mwpag;gl;l M!;j;Jkh nehahspfspy; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ;
Vw;gLk; mjpf ghjpg;gpw;Fk;/  ,uj;jj;jpd; <!;ndh @gpy; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ;
mqf;fspd; vz;zpf;iff;Fk;/ kw;Wk; ,k;KndhFnshg[ypd; ; ; ; ; ; ; ; ; ; [ ;; ; ; ; ; ; ; ; ; [ ;; ; ; ; ; ; ; ; ; [ ; "<" 
mstpw;Fk; cs;s bjhlh;g[; ; ; ; [; ; ; ; [; ; ; ; [" Fwpj;j Ma;tpy; bra;Kiw kw;Wk; 
midj;J tptu';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis 
bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma;tpypUe;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk;  :       ifbahg;gk; / nuif 
ehs; : 
 
 
  
 
MASTER CHART 
Sl 
No Name Age Sex 
Sex 
code 
      
AH 
       
FH       S 
    
F/Wk 
  
           FEV1 %P   
    
Severity G 
AEC       
(/cu.mm) 
 S.IgE 
(IU/ml)     CM 
                  
Pre 
bro 
Post 
Bro    Rev %           
1 Uma S 38 F 2 DA Y W,D,NA >2 62 74 12 Mo UC 380 1242 N 
2 Sharmila 24 F 2 DA Y W,NA >2 25 37 12 S UC 520 740.65 AR 
3 Praveen 18 M 1 DA Y W,D >2 61 76 15 Mo UC 360 688 N 
4 Pushpa 27 F 2 DA Y W,D,C,NA >2 82 96 14 M PC 180 100.42 N 
5 Bani 43 F 2 N Y W,D >2 65 77 12 Mo UC 390 1762 AR 
6 Suresh 18 M 1 DA N W,D,C,NA >2 30 42 12 S UC 580 2500 AR 
7 Mahila 35 F 2 DA N W,D >2 63 77 14 Mo UC 480 355.8 S 
8 Mallika 38 F 2 N N W,D >2 83 95 12 M PC 210 104 AR 
9 Raji 29 F 2 DA,O N W,D,NA >2 64 78 14 Mo UC 290 1150.8 N 
10 Mallika 28 F 2 DA Y W,D,C,NA               >2 30 42 12 S UC 460 1800 AR 
11 Selvan 32 M 1 N N W,D,C,NA                >2 70 84 14 Mo UC 350 1764 O 
12 Laila 40 F 2 DA,O N W,D >2 67 80 13 Mo UC 540 1897.6 N 
13 Saravanan               M 1 DA Y W,D >2 50 62 12 S UC 620 2210 GE 
14 Raju 30 M 1 N Y W,D,C >2 63 70 17 S UC 490 1387 N 
15 Pradeep 27 M 1 DA N W,NA >2 82 98 16 M PC 210 82.68 N 
16 Murugan 38 M 1 N N W,D >2 76 88 12 Mo UC 260 1110 AR 
17 Usha 29 F 2 DA N W,D,C >2 66 78 12 Mo UC 340 1256 N 
18 Biju 31 M 1 O Y W,D >2 72 85 13 Mo UC 460 107 N 
19 Radha 36 F 1 DA N W,D,NA >2 48 62 14 S UC 410 2146 AR 
20 Alagasamy                   1 DA,O Y W,D >2 43 60 17 S UC 570 2162 N 
21 Mini 22 F 2 DA N W,D >2 84 96 12 M PC 230 760 AR 
  
 
22 Girija 29 F 2 DA N W,D >2 80 94 14 M PC 120 98.2 O 
23 Sam Alex                      1 DA N W,D,C >2 72 87 15 Mo UC 330 360 S 
24 Velusamy                 M 1 DA,O Y W,D,C >2 33 50 17 S UC 480 2600 AR,O 
25 Nurjahan 40 F 2 O Y W,D,C >2 67 82 15 Mo UC 370 97 N 
26 Antony                     41 M 1 N N W,D >2 75 90 15 Mo UC 440 1210 AR 
27 Tamarai 27 F 2 DA Y W,D >2 87 91 14 M UC 140 76 AR 
28 Migavel 18 M 1 O Y W,D,C >2 47 52 15 S UC 490 576 O,E 
29 Veeran 25 M 1 DA N W,D >2 82 95 13 M PC 200 770 N 
30 Krishnan 34 M 1 N Y W,D,C >2 61 77 17 Mo UC 330 983 AR 
31 Manikam 30 M 1 DA N W,D,C,NA >2 75 88 13 Mo UC 430 117 N 
32 Sakti 23 F 2 DA N W,D >2 77 90 13 Mo UC 310 880 N 
33 Valli 31 F 2 N N W,D >2 81 95 14 M PC 110 180 AR 
34 Eswari 38 F 2 O Y W,D,C >2 35 50 15 S UC 360 1450 N 
35 Ishwarya 19 F 2 O N W,D >2 69 76 17 Mo UC 270 934 AR 
36 Aisha 23 F 2 FA,O Y W,D >2 44 58 14 S UC 490 1850 N 
37 Nalini 32 F 2 O Y W,D,C >2 82 96 14 M PC 170 236 AR 
38 Kumar 26 M 2 DA Y W,D >2 63 80 17 Mo UC 370 861 N 
39 Leksmi 30 F 2 O N W,D >2 68 82 14 Mo UC 390 768 AR 
40 Subiah 34 F 2 O Y W,D >2 83 97 14 M UC 120 300 N 
41 Jijo 44 M 1 O Y W,D >2 40 58 18 S UC 420 2374 AR,O 
42 Aruchamy 31 M 1 N Y W,D >2 55 70 15 S UC 390 1357 AR,GE 
43 Kasturi 33 F 2 O Y W,D >2 71 87 16 Mo PC 270 868 N 
44 Veena 26 F 2 O Y W,D >2 73 88 15 M PC 130 78 AR 
45 Santhosh 35 M 1 DA,O Y W,D >2 84 98 14 M PC 110 117 N 
46 Balan 48 M 1 O Y W,D >2 45 62 17 S UC 470 1882 AR 
47 Vijaya 30 F 2 N N W,D >2 66 80 14 Mo UC 310 990 N 
48 Liji 29 F 2 O Y W,D,C,NA >2 48 63 15 S UC 460 968 N 
  
 
49 Chandran 32 M 1 O N W,D >2 71 88 17 Mo UC 330 1116 AR 
50 Buvanesh 23 M 1 N N W,D,C >2 63 81 18 Mo PC 410 887 E 
51 Akila 36 F 2 DA Y W,D,NA >2 62 74 12 Mo UC 350 1132 N 
52 Lavanya 24 F 2 DA Y W,NA >2 25 37 12 S UC 510 745.65 AR 
53 Vijay 18 M 1 DA Y W,D >2 61 76 15 Mo UC 360 688 N 
54 Moly 27 F 2 DA Y W,D,NA >2 82 96 14 M PC 190 100.32 N 
55 Revathy 43 F 2 N Y W,D >2 65 77 12 Mo UC 350 1602 AR 
56 Ajeesh 18 M 1 DA N W,D,NA >2 30 42 12 S UC 510 2300 E 
57 Rani 35 F 2 DA N W,D >2 63 77 14 Mo UC 410 720.8 N 
58 Megha 38 F 2 N N W,D >2 83 95 12 M PC 200 124 N 
59 Kalpana 29 F 2 DA,O N W,D,NA >2 64 78 14 Mo UC 230 1150.8 AR 
60 Meera 28 F 2 DA Y W,D,C,NA                >2 30 42 12 S UC 460 1800 N 
61 Ajith 32 M 1 N N W,D,C,NA                >2 70 84 14 Mo UC 350 1364 N 
62 Mariya 40 F 2 DA,O N W,D,C >2 67 80 13 Mo UC 540 1097.6 AR 
63 Amutha 28 F 1 DA,O Y W,D >2 43 60 17 S UC 540 2142 S 
64 Gopika 22 F 2 DA N W,D >2 84 96 12 M PC 210 720 N 
65 Leela 39 F 2 DA N W,D >2 80 94 14 M PC 110 440 AR 
66 Palanisamy     34 M 1 DA N W,C,D >2 72 87 15 Mo UC 320 430 N 
67 Raman 40 M 1 DA,O Y W,C,D >2 33 50 17 S UC 460 2400 AR 
68 Gayatri 34 F 2 O Y W,C,D >2 67 82 15 Mo UC 370 567 AR 
69 Ganesh 41 M 1 N N W,D >2 75 90 15 Mo UC 410 1200 S 
70 Seeta 28 F 2 DA Y W,D >2 87 91 14 M UC 240 416 N 
71 Vijeish 18 M 1 O Y W,C,D >2 47 52 15 S UC 440 2456 AR 
72 Mukil 26 M 1 DA N W,D >2 82 95 13 M PC 190 570 N 
73 Rajesh 37 M 1 N Y W,D,C >2 61 77 17 Mo UC 320 973 AR 
74 Solomon 31 M 1 DA N W,D,C,NA >2 75 88 13 Mo UC 420 176 N 
75 Umaiba 19 F 2 DA Y W,D,C >2 50 62 12 S UC 630 2110 S 
  
 
76 Srinivas 30 M 1 N Y W,D,C >2 63 70 17 S UC 430 1287 AR 
77 Surya 27 M 1 DA N W,D,NA >2 82 98 16 M PC 220 134.68 N 
78 Senthil 38 M 1 N N W,D >2 76 88 12 Mo UC 246 1210 N 
79 Priyanka 28 F 2 DA N W,D,C >2 66 78 12 Mo UC 330 1156 N 
80 Deepak 32 M 1 O Y W,D >2 72 85 13 Mo UC 410 917 AR 
81 Padmini 34 F 1 DA N W,D,NA >2 48 62 14 S UC 310 1046 AR 
82 Victor 29 M 1 DA,O Y W,D >2 43 60 17 S UC 470 962 AR 
83 Valli 22 F 2 DA N W,D >2 84 96 12 M PC 230 98 GE 
84 Devaki 39 F 2 O Y W,D,C >2 35 50 15 S UC 360 1450 N 
85 Tamarai 18 F 2 O N W,D >2 69 76 17 Mo UC 270 934 N 
86 Thilagavathy 33 F 2 FA,O Y W,D >2 44 58 14 S UC 490 1850 S 
87 Lekha 32 F 2 O Y W,D,C >2 82 96 14 M PC 170 236 AR 
88 Vadivel 27 M 2 DA Y W,D >2 63 80 17 Mo UC 360 831 N 
89 Suganti 30 F 2 O N W,D >2 68 82 14 Mo UC 390 768 E 
90 Annapurni 34 F 2 O Y W,D >2 83 97 14 M UC 120 300 N 
91 Jebaraj 44 M 1 O Y W,D >2 40 58 18 S UC 410 2374 N 
92 Katirvel 31 M 1 N Y W,D >2 55 70 15 S UC 230 1057 E 
93 Gitanjali 36 F 2 O Y W,D >2 71 87 16 Mo PC 270 888 N 
94 Rangi 28 F 2 O Y W,D >2 73 88 15 M PC 130 358 AR 
95 Hameed 35 M 1 DA,O Y W,D >2 84 98 14 M PC 100 117 N 
96 Muthu 41 M 1 O Y W,D >2 45 62 17 S UC 460 602 N 
97 Chitra 30 F 2 N N W,D >2 66 80 14 Mo UC 300 210 N 
98 Maratakam 27 F 2 O Y W,D,C,NA >2 48 63 15 S UC 430 918 E 
99 Narayani 31 F 2 DA Y W,D,C,NA                >2 30 42 12 S UC 440 1700 S 
100 Shiva 30 M 1 N N W,D,C,NA                >2 70 84 14 Mo UC 310 904 AR 
 
